Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Hydrocortisone and Iodochlorhydroxyquin
Overview
What is Ala Quin?
Iodochlorhydroxyquin (Clioquinol) is an antifungal agent and a member of a family of drugs called hydroxyquinolines. Chemically, Iodochlorhydroxyquin is 5-chloro-7-iodo-quinolin-8-ol. Its structural formula is:
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Hydrocortisone is a member of this class. Chemically hydrocortisone is pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy, (11β)-. Its structural formula is:
Each gram of ALA-QUIN contains 5 mg Hydrocortisone USP and 30 mg Iodochlorhydroxyquin USP in a cream base consisting of purified water, glycerin, cetyl alcohol, polysorbate 80, stearyl alcohol, sodium lauryl sulfate, cetyl palmitate and sorbic acid.
What does Ala Quin look like?
What are the available doses of Ala Quin?
Sorry No records found.
What should I talk to my health care provider before I take Ala Quin?
Sorry No records found
How should I use Ala Quin?
Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
“Possibly” effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo.
Final classification of the less-than-effective indications requires further investigation.
Apply as a thin layer to the affected areas 2 to 4 times daily or as directed by a physician.
What interacts with Ala Quin?
Hypersensitivity to lodochlorhydroxyquin-Hydrocortisone, or any of its ingredients or related compounds: lesions of the eye, tuberculosis of the skin; most viral skin lesions (including herpes simplex, vaccinia, and varicella).
Patients sensitive to chloroxine, iodine, or iodine-containing preparations may also be sensitive to this medication.
What are the warnings of Ala Quin?
Sorry No Records found
What are the precautions of Ala Quin?
Sorry No Records found
What are the side effects of Ala Quin?
There have been a few reports of rash and hypersensitivity as well as thinning of the skin with easy bruising.
The following local adverse reactions have also been reported with topical corticosteroids and iodochlorhydroxyquin especially under occlusive dressings; burning; itching; irritation; dryness; folliculitis; blistering, peeling, redness, swelling; hypertrichosis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; maceration of the skin, secondary infection; skin atrophy; striae; miliaria or other signs of irritation not present before therapy.
Discontinue therapy if any untoward reaction occurs.
What should I look out for while using Ala Quin?
Hypersensitivity to lodochlorhydroxyquin-Hydrocortisone, or any of its ingredients or related compounds: lesions of the eye, tuberculosis of the skin; most viral skin lesions (including herpes simplex, vaccinia, and varicella).
Patients sensitive to chloroxine, iodine, or iodine-containing preparations may also be sensitive to this medication.
What might happen if I take too much Ala Quin?
Sorry No Records found
How should I store and handle Ala Quin?
PROTECT FROM LIGHT. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in1 ounce tube NDC 0316-0123-0180 grams tube NDC 0316-0123-80 Revised: Oct. 2015Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, Tennessee 37604PRINTED IN USAP8001.04
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Iodochlorhydroxyquin is a broad-spectrum antibacterial and antifungal. Its precise mechanism of action is unknown. Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Non-Clinical Toxicology
Hypersensitivity to lodochlorhydroxyquin-Hydrocortisone, or any of its ingredients or related compounds: lesions of the eye, tuberculosis of the skin; most viral skin lesions (including herpes simplex, vaccinia, and varicella).Patients sensitive to chloroxine, iodine, or iodine-containing preparations may also be sensitive to this medication.
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.
The pharmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling.
General
Staining of skin and fabrics may occur. Additionally, there are rare reports of discoloration (yellowing) of hair and nails. Iodochlorhydroxyquin-Hydrocortisone may prove irritating to sensitized skin in rare cases. If irritation occurs, discontinue therapy. Check with physician if no improvement within 1 to 2 weeks.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Signs and symptoms of systemic toxicity, electrolyte imbalance, or adrenal suppression have not been reported with Iodochlorhydroxyquin-Hydrocortisone. Nevertheless, the possibility of suppression of the HPA axis during therapy should be kept in mind, especially when the drug is used under occlusive dressings, for a prolonged period, or for treating extensive cutaneous areas since significant absorption of corticosteroid may occur under these conditions, particularly in children and infants.
Patients receiving a large dose of a potent topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See )
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
Iodochlorhydroxyquin may be absorbed through the skin and interfere with thyroid function test.
Iodochlorhydroxyquin may cause significant elevation of protein-bound iodine (PBI) or butanol-extractable iodine (BEI) and a decrease in radioactive iodine (RAI) uptake. If such tests are contemplated, wait at least one month between discontinuation of therapy and performance of these tests.
Prolonged use may result in overgrowth of nonsusceptible organisms requiring appropriate therapy. In the presence of systemic infections, appropriate systemic antibiotics should be used.
There have been a few reports of rash and hypersensitivity as well as thinning of the skin with easy bruising.
The following local adverse reactions have also been reported with topical corticosteroids and iodochlorhydroxyquin especially under occlusive dressings; burning; itching; irritation; dryness; folliculitis; blistering, peeling, redness, swelling; hypertrichosis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; maceration of the skin, secondary infection; skin atrophy; striae; miliaria or other signs of irritation not present before therapy.
Discontinue therapy if any untoward reaction occurs.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).